Похоже, при загрузке страницы произошла ошибка.
Наша команда получила уведомление. Если проблема сохранится, свяжитесь с нами через виджет поддерж. по email.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 7,5x - 8,3x | 7,9x |
| Selected Fwd Revenue Multiple | 5,8x - 6,5x | 6,1x |
| Fair Value | 2.217₹ - 2.439₹ | 2.328₹ |
| Upside | -13,3% - -4,6% | -9,0% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Morepen Laboratories Limited | MOREPENLAB | NSEI:MOREPENLAB |
| Lupin Limited | LUPIN | NSEI:LUPIN |
| Abbott India Limited | ABBOTINDIA | NSEI:ABBOTINDIA |
| Alembic Pharmaceuticals Limited | APLLTD | NSEI:APLLTD |
| Zydus Lifesciences Limited | ZYDUSLIFE | NSEI:ZYDUSLIFE |
| Mankind Pharma Limited | MANKIND | NSEI:MANKIND |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| MOREPENLAB | LUPIN | ABBOTINDIA | APLLTD | ZYDUSLIFE | MANKIND | |||
| NSEI:MOREPENLAB | NSEI:LUPIN | NSEI:ABBOTINDIA | NSEI:APLLTD | NSEI:ZYDUSLIFE | NSEI:MANKIND | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 17.1% | 6.4% | 9.7% | 9.6% | 8.2% | 15.7% | ||
| 3Y CAGR | 12.4% | 9.7% | 10.7% | 4.9% | 10.7% | 18.5% | ||
| Latest Twelve Months | 8.6% | 12.9% | 8.5% | 4.9% | 16.9% | 17.0% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | 7.1% | 10.1% | 21.2% | 14.7% | 18.9% | 21.2% | ||
| Prior Fiscal Year | 3.9% | 5.1% | 21.1% | 7.7% | 16.6% | 18.2% | ||
| Latest Fiscal Year | 8.0% | 13.9% | 23.6% | 10.6% | 23.2% | 20.8% | ||
| Latest Twelve Months | 9.7% | 18.8% | 24.4% | 11.2% | 24.6% | 21.1% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 1.72x | 4.22x | 9.96x | 2.83x | 3.89x | 8.72x | ||
| EV / LTM EBIT | 17.7x | 22.4x | 40.9x | 25.3x | 15.8x | 41.3x | ||
| Price / LTM Sales | 1.81x | 4.19x | 10.12x | 2.68x | 3.89x | 9.06x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 1.72x | 3.89x | 9.96x | |||||
| Historical EV / LTM Revenue | 9.07x | 9.07x | 9.07x | |||||
| Selected EV / LTM Revenue | 7.47x | 7.87x | 8.26x | |||||
| (x) LTM Revenue | 116,410 | 116,410 | 116,410 | |||||
| (=) Implied Enterprise Value | 869,962 | 915,749 | 961,537 | |||||
| (-) Non-shareholder Claims * | 42,447 | 42,447 | 42,447 | |||||
| (=) Equity Value | 912,409 | 958,196 | 1,003,984 | |||||
| (/) Shares Outstanding | 412.6 | 412.6 | 412.6 | |||||
| Implied Value Range | 2,211.48 | 2,322.46 | 2,433.44 | |||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2,211.48 | 2,322.46 | 2,433.44 | 2,557.50 | ||||
| Upside / (Downside) | -13.5% | -9.2% | -4.9% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | MOREPENLAB | LUPIN | ABBOTINDIA | APLLTD | ZYDUSLIFE | MANKIND | |
| Enterprise Value | 30,701 | 927,381 | 620,759 | 181,455 | 841,964 | 1,012,723 | |
| (+) Cash & Short Term Investments | 1,864 | 29,123 | 11,057 | 1,290 | 24,950 | 47,267 | |
| (+) Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Debt | (335) | (34,425) | (605) | (10,664) | (1,905) | (4,821) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 32,231 | 922,079 | 631,211 | 172,081 | 865,009 | 1,055,170 | |
| (/) Shares Outstanding | 548.0 | 456.6 | 21.2 | 196.6 | 1,006.2 | 412.6 | |
| Implied Stock Price | 58.82 | 2,019.60 | 29,705.00 | 875.45 | 859.65 | 2,557.50 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 58.82 | 2,019.60 | 29,705.00 | 875.45 | 859.65 | 2,557.50 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |